Amélie Lusque

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

J. Mazieres, Alexander Drilon, Amélie Lusque et al. · Annals of Oncology · 2019 · 1.4K citations · Full text

Life Sciences, Immunology, Oncology +17

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

Myriam Delaunay, J. Cadranel, Amélie Lusque et al. · European Respiratory Journal · 2017 · 421 citations · Full text

Medicine, Immunology, Oncology +15

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial

Fernanda Mosele, Élise Deluche, Amélie Lusque et al. · Nature Medicine · 2023 · 370 citations · Full text

Medicine, Oncology, Pharmacology +17

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Fernanda Mosele, Bojana Stefanovska, Amélie Lusque et al. · Annals of Oncology · 2020 · 320 citations · Full text

Medicine, Cancer Biology, Oncology +14

PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab

Nicolas Guibert, Myriam Delaunay, Amélie Lusque et al. · Lung Cancer · 2018 · 232 citations

Medicine, Immunology, Oncology +14